8 results about "Coagulation factor VII" patented technology

The invention discloses a purification method and application of a recombinant human blood coagulation factor VII. The purification method comprises the following steps: adding a His tag into a blood coagulation factor VII gene sequence, then sequentially performing cell culture, clarification treatment, ultrafiltration concentration, nickel column affinity chromatography and anion chromatography, and finally performing self-activation to obtain the recombinant human blood coagulation factor VII. Wherein in the nickel column affinity chromatography process, the chromatography sample loading concentration is 500-1000 [mu] g / ml, and the equilibrium liquid comprises 0.5-1.0 mol / L of NaCl. According to the purification method, the purity of the recombinant blood coagulation factor VII is improved, the uniformity of the recombinant blood coagulation factor VII is higher, the specific activity of the recombinant blood coagulation factor VII is 975 IU / mg, the recombinant blood coagulation factor VII contains few other protein components, and adverse reactions caused by other components can be reduced; the cost in the production process of the recombinant blood coagulation factor VII is reduced, a specific monoclonal antibody does not need to be used, and the process cost is reduced; the production process steps of the recombinant blood coagulation factor VII are reduced, and the recovery rate is increased.

The invention discloses a hemostatic peptide capable of targeting to a bleeding focus as well as a preparation method and application of the hemostatic peptide, and the hemostatic peptide is characterized in that the amino acid sequence of the hemostatic peptide is RKLFFVRTA. According to the present invention, the key amino acid sequence combined with TF in the blood coagulation factor VII (FVII) is adopted as the basis for modification, the exposed TF (blood coagulation starting factor) after the blood vessel injury is specially identified, the specific expression of the TF at the bleeding site is adopted to achieve the precise targeting, the interference on the normal blood vessel is reduced, and the unnecessary thrombus risk is reduced from the source.

The present invention relates to the technical field of blood product production, and specifically relates to a method for extracting and separating IgM and coagulation factor VII from plasma. The method comprises the following steps: after the cold glue plasma is adjusted in pH value and conductivity, it is loaded onto a first anion exchange chromatography column, and then sequentially eluted with a first eluent and a second eluent to obtain a first ion chromatography product; after the first ion chromatography product is ultrafiltered, dialyzed, and adjusted in pH value and conductivity, it is loaded onto a gel filtration chromatography column, and the flow-through solution corresponding to the first ultraviolet peak and the flow-through solution corresponding to the third ultraviolet peak are respectively collected to obtain a first gel filtration chromatography product containing IgM and a second gel filtration chromatography product containing coagulation factor VII. This technical solution can solve the technical problem that the existing preparation process cannot simultaneously purify and enrich IgM and human coagulation factor VII, and at the same time ensure the product quality, improve the utilization rate of plasma raw materials, and has ideal practical application value.

The present application relates to saRNA and oligonucleotide modulators for the prevention or treatment of FVII related diseases, conditions or disorders and uses thereof, such as diseases caused by or related to insufficient expression of the FVII gene or bleeding complications caused by hemophilia with inhibitors. The present application also relates to a pharmaceutical composition comprising an oligonucleotide modulator and a method of preventing or treating FVII-related diseases, conditions or disorders induced by insufficient FVII levels with the oligonucleotide modulator disclosed herein.

The present invention discloses a prothrombin time detection reagent and a preparation method thereof. Among them, the prothrombin time detection reagent is prepared from rabbit brain powder, a solvent, sodium chloride, a surfactant, a metal salt, a reducing agent, and calcium chloride. It can effectively remove coagulation factor VII, so that the prepared thromboplastin does not contain coagulation factor VII, making the prepared prothrombin time detection reagent highly sensitive to coagulation factor VII, ensuring the detection accuracy and improving its actual use effect.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor VII, CA 19-9, Insulin-like growth factor-binding protein 7, C-X-C motif chemokine 6, and C-C motif chemokine 13 as diagnostic and prognostic biomarkers in renal injuries.

The present invention discloses a purification method and application of recombinant human coagulation factor VII. The purification method comprises the following steps: adding a His tag to the coagulation factor VII gene sequence, then sequentially performing cell culture, clarification treatment, ultrafiltration concentration, nickel column affinity chromatography, anion chromatography, and finally self-activation to obtain recombinant human coagulation factor VII; wherein, during the nickel column affinity chromatography process, the chromatography loading concentration is 500-1000 μg / ml, and the equilibrium solution includes 0.5-1.0 mol / L NaCl. The purification method of the present invention improves the purity of recombinant coagulation factor VII and makes it more homogeneous. The recombinant coagulation factor VII of the present invention has a specific activity of 975 IU / mg, contains less other protein components, and can reduce the adverse reactions caused by other components; reduces the cost in the production process of recombinant coagulation factor VII, does not need to use specific monoclonal antibodies, and reduces the process cost; also reduces the production process steps of recombinant coagulation factor VII and improves the recovery rate.